Reforgene ranks in the 2021 healthcare Top 15 Best Emerging Enterprise award
On May 26, 2022, CHC Medical Consulting, together with CITIC Securities, officially released the "2021 Annual China Healthcare Industry Investment and Financing Honor List". As an authoritative list in the healthcare field from a third-party perspective, the China Healthcare Industry Investment and Financing Honor List has been held since 2018. Based on a review of the current state of investment and financing development in the healthcare industry and upholding the principles of fairness, impartiality and objective neutrality, it is produced through data statistics, horizontal comparison and full-dimensional analysis, aiming to commend the value contributors in the healthcare field in 2021, set industry benchmarks, and explore the hard strength behind quality investment institutions, listed companies and innovative enterprises.
Reforgene was selected into the 2021 Healthcare Best Emerging Enterprise Award TOP15, demonstrating its independent innovation, rapid growth and unlimited potential. Reforgene is a leading innovative gene medicine enterprise in China, driven by gene editing technology and dedicated to the birth of novel medicines. It currently has pipeline programs in genetic diseases, complex diseases and oncology, among which its beta-thalassemia gene editing therapy has achieved globally leading clinical progress.
About CHC Medical Consulting
CHC Medical Consulting is a value platform focused on the healthcare industry, committed to providing online and offline professional services for domestic and international medical enterprises, investment institutions and medical industrial parks through years of in-depth research and extensive cooperation in the medical professional field and its accumulation in the capital market, helping medical practitioners obtain the latest industry information and promote cooperation and exchange.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.